NCT01826461 - An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis | Biotech Hunter

Enrollment

151

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Atopic Dermatitis

Interventions

DRUG

PDI-192

DRUG

Vehicle

Trial Locations (9)

UCSD - Rady Children's Hospital, San Diego

Northwestern University, Chicago

Sneeze, Wheeze & Itch Associates, LLC, Normal

Minnesota Clinical Study Center, Fridley

Academic Dermatology Associates, Albuquerque

Dermatology Consulting Services, High Point

DermResearch, Inc., Austin

UT Houston Health Science Center, Houston

Virginia Clinical Research, Inc., Norfolk